SBI Mutual Fund and HDFC Mutual Fund purchased shares of Anthem Biosciences via bulk deals on the Bombay Stock Exchange. The move underscores growing institutional confidence in the pharmaceutical and biotech sector, with Anthem Biosciences positioned as a key player in drug discovery and contract research.
SBI Mutual Fund and HDFC Mutual Fund executed bulk deals to acquire shares in Anthem Biosciences, signaling strong institutional interest in the pharmaceutical company. The transactions, recorded on the Bombay Stock Exchange (BSE), highlight confidence in the sector’s growth potential as Anthem Biosciences continues to strengthen its position in drug discovery, contract research, and manufacturing.
Key Highlights
-
SBI Mutual Fund and HDFC Mutual Fund executed bulk deals in Anthem Biosciences on the Bombay Stock Exchange
-
The transactions indicate strong institutional confidence in Anthem Biosciences’ growth trajectory within pharmaceuticals and biotech
-
Anthem Biosciences operates in drug discovery, contract research, and manufacturing, making it a strategic investment target
-
Bulk deals by mutual funds often signal long-term conviction in a company’s fundamentals and sectoral outlook
-
The move comes amid broader investor interest in healthcare and biosciences, sectors expected to benefit from innovation and rising demand
The participation of two of India’s largest mutual funds underscores Anthem Biosciences’ appeal as a growth-oriented company in a sector that continues to attract capital inflows. These deals may also influence broader market sentiment toward pharmaceutical and biotech stocks.
Sources: BSE Data, Indira Securities